<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982358</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489A2423</org_study_id>
    <secondary_id>Ek#2140</secondary_id>
    <nct_id>NCT00982358</nct_id>
  </id_info>
  <brief_title>Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A 16-weeks, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Anti-inflammatory Actions of 320 mg Diovan in Patients With Type 2 Diabetes With and Without Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      This study is designed to support the use of valsartan in the diabetic population. Two&#xD;
      different groups will be studied, one with and one without coronary artery disease (CAD)&#xD;
      documented by angiography.&#xD;
&#xD;
      The study is intended to demonstrate that valsartan 320 mg has an anti-inflammatory&#xD;
      potential, reducing inflammatory serum markers as well as inflammatory gene expression, and&#xD;
      to show that valsartan is able to improve metabolic parameters in this patient population.&#xD;
      Furthermore, in the subgroup of patients with documented CAD this study wants to show that&#xD;
      valsartan improves coronary perfusion.&#xD;
&#xD;
      3 Objectives&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
        1. To demonstrate the anti-inflammatory efficacy of valsartan 160/320 mg by testing the&#xD;
           hypothesis of superiority compared to placebo in the reduction of the inflammatory&#xD;
           marker Tumor necrosis factor alpha (TNFα) in plasma after 16 weeks of treatment in&#xD;
           hypertensive patients with type 2 diabetes mellitus.&#xD;
&#xD;
        2. To demonstrate the anti-inflammatory efficacy of valsartan 160/320 mg by testing the&#xD;
           hypothesis of superiority compared to placebo in the reduction of the inflammatory&#xD;
           marker Interleukin 6 (IL-6) in plasma after 16 weeks of treatment in hypertensive&#xD;
           patients with type 2 diabetes mellitus.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To explore the effect of 160/320 mg valsartan on parameters of insulin sensitivity.&#xD;
&#xD;
        2. To explore the effect of 160/320 mg valsartan on additional inflammatory markers in&#xD;
           plasma [e.g. C-Reactive protein (CRP), soluble intracellular adhesion molecule-1&#xD;
           (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), serum amyloid A (SAA),&#xD;
           soluble CD40 ligand (sCD40L), fibrinogen, Interleukin 1β (IL-1β), matrix&#xD;
           metalloproteases -2, -3 and -9 (MMP-2, -3, -9), and sE-selectin)].&#xD;
&#xD;
        3. To explore the effect of 160/320 mg valsartan on inflammatory gene expression from&#xD;
           monocytes and fat tissue.&#xD;
&#xD;
        4. To explore the effect of 160/320 mg valsartan on metabolic gene expression in fat&#xD;
           tissue.&#xD;
&#xD;
        5. To explore the effect of 160/320 mg valsartan on coronary perfusion, in the group of&#xD;
           patients with angiographically documented CAD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study was to evaluate the anti-inflammatory effect of VAL by analyzing the reduction of the inflammatory markers interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα) in serum after 16 weeks of treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To explore the effect of 160/320 mg valsartan on parameters of insulin sensitivity.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the effect of 160/320 mg valsartan on additional inflammatory markers in plasma</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the effect of 160/320 mg valsartan on inflammatory gene expression from monocytes and fat tissue</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the effect of 160/320 mg valsartan on metabolic gene expression in fat tissue.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the effect of 160/320 mg valsartan on coronary perfusion, in the group of patients with angiographically documented CAD</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>121</enrollment>
  <condition>Hypertension</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients between 30 and 80 years old, inclusive&#xD;
&#xD;
          -  Controlled type 2 Diabetes Mellitus on stable treatment at least during the 4 weeks&#xD;
             prior to visit 1&#xD;
&#xD;
          -  Treated or untreated stage 1 (according to JNC VII Guidelines) or grade 1 (according&#xD;
             to ESH/ESC 2003 Guidelines) hypertensive patients&#xD;
&#xD;
          -  For one stratum: angiographically proven CAD&#xD;
&#xD;
          -  Signed informed consent prior to any study procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertension classified as stage 2 (or grade 2) or higher&#xD;
&#xD;
          -  Normotensive patients, i.e. patients who do not have a history of high blood pressure,&#xD;
             and who are not receiving any antihypertensive medication&#xD;
&#xD;
          -  Treatment with more than 2 antihypertensive medications&#xD;
&#xD;
          -  Current treatment with ARBs&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1c) &gt;8.5% at Visit 1&#xD;
&#xD;
          -  Current treatment with glitazones&#xD;
&#xD;
          -  Myocardial infarction less than 3 months prior to Visit 1&#xD;
&#xD;
          -  Total cholesterol &gt;7.8 mmol/l&#xD;
&#xD;
          -  Past diagnosis of any systemic inflammatory disease&#xD;
&#xD;
          -  Known or suspected contraindications, including history of allergy to angiotensin&#xD;
             receptor blockers&#xD;
&#xD;
          -  History of hypertensive encephalopathy or cerebrovascular accident less than 1 year&#xD;
             prior to Visit 1&#xD;
&#xD;
          -  Known Keith-Wagener grade III or IV hypertensive retinopathy&#xD;
&#xD;
          -  History of heart failure&#xD;
&#xD;
          -  Second or third degree heart block without a pacemaker&#xD;
&#xD;
          -  Concomitant unstable angina pectoris&#xD;
&#xD;
          -  Concurrent potential life threatening arrhythmia or symptomatic arrhythmia&#xD;
&#xD;
          -  Clinically significant valvular heart disease&#xD;
&#xD;
          -  Evidence of hepatic disease as determined by any one of the following: ALT or AST&#xD;
             values &gt; 2 x ULN at Visit 1, a history hepatic encephalopathy, a history of esophageal&#xD;
             varices, or a history of portocaval shunt&#xD;
&#xD;
          -  Evidence of renal impairment as determined by any one of the following: serum&#xD;
             creatinine &gt;1.25 x ULN at visit 1, a history of dialysis, or a history of nephritic&#xD;
             syndrome&#xD;
&#xD;
          -  Sodium value &lt;132 mmol/L at Visit 1&#xD;
&#xD;
          -  Serum potassium values &lt;3.5 mmol/L or &gt;5.5 mmol/L at visit 1&#xD;
&#xD;
          -  Any surgical or medical condition which might alter the absorption, distribution,&#xD;
             metabolism, excretion of any drug&#xD;
&#xD;
          -  Female patients who are not either post-menopausal for one year of surgically sterile,&#xD;
             and who are not using effective contraceptive methods such as barrier method with&#xD;
             spermicidal or an intra-uterine device. Oral contraceptive use or dermal implants as&#xD;
             the only means of contraception are disallowed&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Any surgical or medical condition which, at the discretion of the investigator, place&#xD;
             the patient at higher risk from his/her participation in the study, or are likely to&#xD;
             prevent the patients from complying with the requirements of the study or completing&#xD;
             the trial period&#xD;
&#xD;
          -  History of malignancy including leukemia and lymphoma within 5 years prior to Visit 1&#xD;
&#xD;
          -  History of any severe, life threatening disease within the past five years&#xD;
&#xD;
          -  Any previous history of a systemic autoimmune disease&#xD;
&#xD;
          -  History of drug or alcohol abuse within the last two years&#xD;
&#xD;
          -  Participation in any investigational drug trial within one month prior to visit 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University of Ulm, Department of Internal Medicine II</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité University Medicine Berlin, Center for Cardiovascular Research, Outpatient Clinic</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <last_update_submitted>September 22, 2009</last_update_submitted>
  <last_update_submitted_qc>September 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Thomas Unger, M.D.</name_title>
    <organization>Charité-University Medicine Berlin, Germany</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

